Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit
Xilio Therapeutics, a biotechnology firm specializing in immuno-oncology therapies, announced that CEO René Russo will speak at Citi’s 2023 Virtual Oncology Leadership Summit on February 23, 2023, at 9:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xilio Therapeutics, a biotechnology firm specializing in immuno-oncology therapies, announced that CEO René Russo will speak at Citi’s 2023 Virtual Oncology Leadership Summit on February 23, 2023, at 9:00 a.m. ET. The live presentation will be available on the company's website, with a replay accessible for 30 days post-event. Xilio is focused on developing tumor-activated therapies aimed at improving cancer treatment outcomes while minimizing side effects. Their innovative approach utilizes proprietary technology to target anti-tumor activity specifically within the tumor microenvironment, with multiple programs currently in clinical and preclinical stages.
Details
News Market Reaction – XLO
The recorded move for XLO in the trading session of this news was +2.20%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in Citi’s 2023 Virtual Oncology Leadership Summit on Thursday, February 23, 2023, at 9:00 a.m. ET.
A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to build a pipeline of novel, tumor-activated molecules, including cytokines and other biologics, which are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment. Xilio is currently advancing multiple programs for tumor-activated I-O treatments in clinical development, as well as programs in preclinical development. Learn more by visiting www.xiliotx.com and follow us on Twitter (@xiliotx) and LinkedIn (Xilio Therapeutics, Inc.).
This press release contains hyperlinks to information that are not deemed to be incorporated by reference in this press release.
For Investor Inquiries:
Melissa Forst
Argot Partners
xilio@argotpartners.com
For Media Inquiries:
Julissa Viana
Vice President, Corporate Communications
media@xiliotx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.